Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: Improved canner therapy administered to a nude mouse model in relation to the internal radiation dosimetry

Cancer

Volumn 80, Issue 12 SUPPL., 1997, Pages 2591-2610

  Behr, Thomas M ^a,b   Sharkey, Robert M ^a   Sgouros, George ^c   Blumenthal, Rosalyn D ^a   Dunn, Robert M ^a   Kolbert, Katherine ^c   Griffiths, Gary L ^d   Siegel, Jeffry A ^a   Becker, Wolfgang S ^b   Goldenberg, David M ^a  

^a CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d IMMUNOMEDICS INC   (United States)

Author keywords

Cationic amino acids; Cross organ radiation; Dosimetry; Monoclonal antibody fragments; Radiation nephritis; Radioimmunotherapy; Radiometals; Renal uptake; Yttrium 90

Indexed keywords

ANTIBODY CONJUGATE; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY Y 90; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER GRAFT; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; COLON CARCINOMA; CONFERENCE PAPER; CONTROLLED STUDY; DOSE CALCULATION; DOSIMETRY; FEMALE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NEPHROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUDE MOUSE; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; XENOGRAFT;

EID: 0031459449     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19971215)80:12+<2591::aid-cncr35>3.0.co;2-5     Document Type: Conference Paper

References (50)

1. Goldenberg DM, editor. Cancer imaging with radiolabeled antibodies. Boston: Kluwer Academic Publishers, 1990.
2. Goldenberg DM, editor. Cancer therapy with radiolabeled antibodies. Boca Raton: CRC Press, 1995.
3. Krenning EP, Bakker WH, Kooij PP, Breeman WA, Oei HY, De long M, et al. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med 1992;33:652-8.
4. Sharkey RM, Weadock KS, Natale A, Haywood L, Aninipot R, Blumenthal RD, et al. Successful radioimmunotherapy for lung metastasis of human colonic cancer in nude mice. J Natl Cancer Inst 1991;83:627-32.
5. 131I-labeled anti-CEA murine monoclonal antibody IgG. J Nucl Med 1997;38:858-70.
6. 131I-labeled anti-CEA antibodies. J Nucl Med 1996;37:875-81.
7. Blumenthal RD, Sharkey RM, Natale AM, Kashi R, Wong G, Goldenberg DM. Comparison of equitoxic radioimmunotherapy and chemotherapy in the treatment of human colonic cancer xenografts. Cancer Res 1994;54:142-51.
8. Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993;329:1219-24.
9. 99mTc-labeled anti-CEA monoclonal antibodies for immunoscintigraphy in colorectal cancer. J Nucl Med 1995; 36:430-41.
10. 99mTc: the role of metabolism and kinetics. Cancer Res 1995;55:5777s-5785s.
11. Kwekkeboom DJ, Krenning EP, Bakker WH, Oei HY, Kooij PPM Lamberts SWJ. Somatostatin analogue scintigraphy in carcinoid tumours. Eur J Nucl Med 1993;20:283-92.
12. Behr T, Becker W, Koch W, Grebmeier J, Wolf F. Somatostatin-Rezeptor-Szintigraphie bei neuroendokrinen Tumoren am Beispiel einer Patientin mit hepatisch metastasiertem Gastrinom. Z Gastroenterol 1994;32:100-4.
13. Behr TM, Sharkey RM, Juweid ME, Blumenthal RD, Dunn RM, Griffiths GL, et al. Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res 1995;55:3825-34.
14. Behr TM, Becker WS, Sharkey RM, Juweid ME, Dunn RM, Bair HJ, et al. Reduction of the renal uptake of monoclonal antibody fragments by amino acid infusion. J Nucl Med 1996;37:829-33.
15. Pimm MV, Gribben SJ. Prevention of renal tubule reabsorption of radiometal (indium-111) labelled Fab fragment of a monoclonal antibody in mice by systemic administration of lysine. Eur J Nucl Med 1994;21:663-5.
16. Stein R, Goldenberg DM, Thorpe SR, Basu A, Mattes MJ. Effects of radiolabeling monoclonal antibodies with a residualizing iodine radiolabel on the accretion of radioisotope in tumors. Cancer Res 1995;55:3132-9.
17. Duncan JR, Behr TM, DeNardo SJ. Intracellular fate of radiometals. J Nucl Med 1997;38:829.
18. Behr TM, Goldenberg DM. Improved prospects for cancer therapy with radiolabeled antibody fragments and peptides. J Nucl Med 1996;37:834-6.
19. Maack T, Johnson V, Kann ST, Figueiredo J, Sigulem D. Renal filtration, transport, and metabolism of low molecular weight proteins: a review. Kidney Int 1979;16:251-70.
20. Silbernagl S. The renal handling of amino acids and oligo-peptides. Physiol Rev 1988;68:912-86.
21. Goldenberg DM, Witte S, Elster K. GW-39: A new human tumor serially transplantable in the golden hamster. Transplantation 1996;4:760-4.
22. Sharkey RM, Goldenberg DM, Murthy S, Pinsky H, Vagg R, Pawlyk D, et al. Clinical evaluation of tumor targeting with a high-affinity, anticarcinoembryonic antigen-specific murine monoclonal antibody, MN-14. Cancer 1993;71:2082-96.
23. Brechbiel MW, Gansow OA, Achter RW, Schlom J, Esteban JM, Simpson DE, et al. Synthesis of 1-(p-isothiocyanobenzyl) derivatives of DTPA and EDTA: antibody labeling and tumor imaging studies. Inorg Chem 1986;25:2772-81.
24. Sharkey RM, Motta-Hennessy C, Pawlyk D, Siegel JA, Goldenberg DM. Biodistribution and radiation dose estimates for yttrium- and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts. Cancer Res 1990;50:2330-6.
25. Siegel JA, Stabin MG. Absorbed fractions for electrons and beta particles in spheres of various sizes. J Nucl Med 1994;35:152-6.
26. Siegel JA, Stabin MG. Absorbed fractions for electrons and beta particles in small spheres. J Nucl Med 1988;29:803.
27. Hui TE, Poston JW. A model of the circulating blood for use in radiation dose calculations. In: Proceedings of the International Conference on Radiation Dosimetry and Safety, Taiwan, 1987:151-68.
28. Loevinger R, Japha EM, Brownell GL. Discrete radioisotope sources. In: Hine GL, Brownell GL, editors. Radiation dosimetry. New York: Academic Press, 1956.
29. Hui TE, Fisher DR, Kuhn JA, Williams LE, Nourigat C, Badger CC, et al. A mouse model for calculating cross-organ beta doses from yttrium-90-labeled immunoconjugates. Cancer 1994;73:951-7.
30. Sgouros G, Barest G, Thekkumthala J, Chui C, Mohan R, Bigler RE, et al. Treatment planning for internal radionuclide therapy: three-dimensional dosimetry for nonuniformly distributed radionuclides. J Nucl Med 1990;31:1884-91.
31. Sgouros G, Chiu S, Pentlow KS, Brewster LI, Kalaigian H, Baldwin B, et al. Three-dimensional dosimetry for radioimmunotherapy treatment planning. J Nucl Med 1993;34:1595-1601.
32. Kolbert K, Sgouros G, Scott AM, Baldwin B, Zhang I, Kalaigian H, et al. Dose-volume histogram representation of patient dose distribution in three-dimensional internal dosimetry [abstract]. J Nucl Med 1994;35:123P-124P.
33. Simpkin DJ, Mackie TR. EGS4 Monte Carlo determination of the beta dose kernel in water. Med Phys 1990;17:179-86.
34. Pawlak-Byczkowska EJ, Hansen HJ, Dion AS, Goldenberg DM. Two new monoclonal antibodies, EPB-1 and EPB-2, reactive with human lymphoma. Cancer Res 1989;49:4568-77.
35. Blumenthal RD, Sharkey RM, Forman D, Wong G, Hess J, Goldenberg DM. Improved experimental cancer therapy by radioantibody dose intensification as a result of syngeneic bone marrow transplantation. Exp Hematol 1995;23:1088-97.
36. Blumenthal RD, Kashi R, Sharkey RM, Goldenberg DM. Quantitative and qualitative effects of experimental radioimmunotherapy on tumor vascular permeability. Int J Cancer 1995; 61: 557-66.
37. Pearse HD. The kidney. In: Cox JD, editor. Moss' radiation oncology: rationale, technique, results. St. Louis: Mosby, 1994: 499-517.
38. Luxton RW. Radiation nephritis: a long-term study of 54 patients. Lancet 1961;2:1221-4.
39. Madrazo AA, Churg J. Radiation nephritis: chronic changes following moderate doses of radiation. Lab Invest 1976; 34:283-90.
40. Kunkler PB, Farr RF, Luxton RW. The limit of renal tolerance to X-rays: an investigation into renal damage occurring following the treatment of tumours of the testis by abdominal baths. Br J Radiol 1952;25:190-201.
41. Luxton RW. Radiation nephritis. Q J Med 1953;22:215-42.
42. Luxton RW. The clinical and pathological effects of renal irradiation. In: Buschke F, editor. Progress in radiation therapy. New York: Grune & Stratton, 1962:15-34.
43. Asscher AW. The delayed effects of renal irradiation. Clin Radiol 1964;15:320-5.
44. Avioli LV, Lazor MZ, Cotlove E, Brace KC, Andrews JR. Early effects of radiation on renal function in man. Am J Med 1963;34:329-37.
45. Dewit L, Anninga JK, Hoefnagel CA, Nooijen WJ. Radiation injury in the human kidney: a prospective analysis using specific scintigraphic and biochemical endpoints. Int J Radiat Oncol Biol Phys 1990;19:977-83.
46. Bender H, Zamora PO, Biersack HJ. Scintigraphic behavior and therapy dose estimates from loco-regionally applied Re-188 somatostatin analog RC160 [abstract]. J Nucl Med 1995;36:183P-184P.
47. Wyngaarden JB, Smith LH Jr., editors. Cecil textbook of medicine. Philadelphia: W. B. Saunders, 1988.
48. Goris ML, Nielsen KK, Napel SA. Dosimetry computation from tissue distribution data entered in an electronic mouse model with convolution of the beta ray deposition profile [abstract]. J Nucl Med 1994;35:161P.
49. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med 1993;34:689-94.
50. Goddu SM, Howell RW, Rao DV. Biologic dosimetry of bone marrow: implications for radionuclide therapy [abstract]. Tumor Targeting 1996;2:146.